Cover Image
市場調查報告書

腎臟移植:開發中產品分析

Kidney Transplantation - Pipeline Review, H1 2016

出版商 Global Markets Direct 商品編碼 251607
出版日期 內容資訊 英文 176 Pages
訂單完成後即時交付
價格
Back to Top
腎臟移植:開發中產品分析 Kidney Transplantation - Pipeline Review, H1 2016
出版日期: 2016年04月20日 內容資訊: 英文 176 Pages
簡介

腎臟移植,是各種腎臟疾病所採用的治療方法。腎臟移植,把受傷害患病的腎臟換成健康的腎臟。移植相關原因的危險因素是出血,感染疾病,血栓,心血管障礙。移植後,免疫系統可能將移植的腎臟判斷為異物,而起排斥作用。於是,患者產生併發症,最終有拒絕新內臟器官的可能性。因此,同時施給免疫抑制劑,防止內臟器官的排斥反應,使其成功移植。

本報告提供腎臟移植相關的藥物的開發情形調查分析,開發中產品的概要,臨床實驗的各階段的產品概要,主要企業簡介,藥物簡介,開發中產品的最新趨勢,最新消息和新聞稿等相關的系統性資訊。

簡介

  • 調查範圍

腎臟移植概要

治療藥的開發

  • 開發中產品的概要
  • 開發中產品比較分析

腎臟移植:企業開發中的治療藥

腎臟移植:大學/機關研究中的治療藥

腎臟移植:開發中產品概況

  • 後期階段的產品
  • 臨床階段的產品
  • 初期階段的產品
  • 開發階段不明的產品

腎臟移植:企業開發中的產品

腎臟移植:大學/機關研究中的產品

腎臟移植的治療藥的開發企業

  • Alexion Pharmaceuticals, Inc.
  • Amgen Inc.
  • Amyndas Pharmaceuticals LLC
  • Angion Biomedica Corp.
  • Astellas Pharma Inc.
  • Bio-inRen
  • Catalyst Biosciences, Inc.
  • Corline Biomedical AB
  • CSL Limited
  • Digna Biotech, S.L.
  • Dompe Farmaceutici S.p.A.
  • Effimune SAS
  • FibroGen, Inc.
  • GlaxoSmithKline Plc
  • Grifols, S.A.
  • Hansa Medical AB
  • Kyowa Hakko Kirin
  • Mabtech Limited
  • Noorik Biopharmaceuticals AG
  • Novartis AG
  • Opsona Therapeutics Limited
  • Pharming Group N.V.
  • Prolong Pharmaceuticals, LLC
  • Quark Pharmaceuticals, Inc.
  • Shire Plc
  • t-cell Europe GmbH
  • Tiziana Life Sciences Plc
  • Zyrnat Biotherapeutics SL

腎臟移植:治療藥的評估

  • 單劑產品
  • 各標的
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

藥物簡介

腎臟移植:最近的開發平台趨勢

腎臟移植:暫停中的計劃

腎臟移植:開發中止的產品

腎臟移植:產品開發的里程碑

  • 主要消息和新聞稿

附錄

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC7832IDB

Summary

Global Markets Direct's, 'Kidney Transplantation - Pipeline Review, H1 2016', provides an overview of the Kidney Transplantation pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Kidney Transplantation, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Kidney Transplantation and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Kidney Transplantation
  • The report reviews pipeline therapeutics for Kidney Transplantation by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved Kidney Transplantation therapeutics and enlists all their major and minor projects
  • The report assesses Kidney Transplantation therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news related to pipeline therapeutics for Kidney Transplantation

Reasons to buy

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for Kidney Transplantation
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Kidney Transplantation pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Kidney Transplantation Overview
  • Therapeutics Development
    • Pipeline Products for Kidney Transplantation - Overview
    • Pipeline Products for Kidney Transplantation - Comparative Analysis
  • Kidney Transplantation - Therapeutics under Development by Companies
  • Kidney Transplantation - Therapeutics under Investigation by Universities/Institutes
  • Kidney Transplantation - Pipeline Products Glance
    • Late Stage Products
    • Clinical Stage Products
    • Early Stage Products
    • Unknown Stage Products
  • Kidney Transplantation - Products under Development by Companies
  • Kidney Transplantation - Products under Investigation by Universities/Institutes
  • Kidney Transplantation - Companies Involved in Therapeutics Development
    • Alexion Pharmaceuticals, Inc.
    • Amgen Inc.
    • Amyndas Pharmaceuticals LLC
    • Angion Biomedica Corp.
    • Astellas Pharma Inc.
    • Bio-inRen
    • Catalyst Biosciences, Inc.
    • Corline Biomedical AB
    • CSL Limited
    • Digna Biotech, S.L.
    • Dompe Farmaceutici S.p.A.
    • Effimune SAS
    • FibroGen, Inc.
    • GlaxoSmithKline Plc
    • Grifols, S.A.
    • Hansa Medical AB
    • Kyowa Hakko Kirin Co., Ltd.
    • Mabtech Limited
    • Noorik Biopharmaceuticals AG
    • Novartis AG
    • Opsona Therapeutics Limited
    • Pharming Group N.V.
    • Prolong Pharmaceuticals, LLC
    • Quark Pharmaceuticals, Inc.
    • Shire Plc
    • t-cell Europe GmbH
    • Tiziana Life Sciences Plc
    • Zyrnat Biotherapeutics SL
  • Kidney Transplantation - Therapeutics Assessment
    • Assessment by Monotherapy Products
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Drug Profiles
    • albumin (human) - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • AMY-101 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • AS-2521780 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • basiliximab biobetter - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • BB-3 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • belimumab - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • bleselumab - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • BRN-1889 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • C1 esterase inhibitor (human) - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • C1 esterase inhibitor (human) - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • C1 esterase inhibitor (recombinant) - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Cardiotrophin-1 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • carfilzomib - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • CB-2782 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Cellular Immunotherapy for Kidney Transplant - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Cellular Immunotherapy for Kidney Transplantation - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Cellular Immunotherapy for Kidney Transplantation - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Cellular Immunotherapy for Multiple Sclerosis and Kidney Transplantation - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • CFZ-533 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • eculizumab - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • EFFI-7H - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • FCR-001 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • FG-4497 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • foralumab - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • FR-104 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • FX-06 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Monoclonal Antibody to Inhibit CD47 for Cardiovascular Disease, Kidney Transplantation and Oncology - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • MRX-109 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • N-003 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • OPN-305 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • QPI-1002 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Recombinant Enzyme to Inhibit Immunoglobulin G for Kidney Transplantation - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Renaparin - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • reparixin - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Sanguinate - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • TNT-009 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • ZY-11 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • Kidney Transplantation - Recent Pipeline Updates
  • Kidney Transplantation - Dormant Projects
  • Kidney Transplantation - Discontinued Products
  • Kidney Transplantation - Product Development Milestones
    • Featured News & Press Releases
      • Apr 04, 2016: FDA clears Hansa Medical's IND application for IdeS in kidney transplantation
      • Mar 11, 2016: Study results presented in New England Journal of Medicine strengthen Hansa Medical belief in the potential of IdeS
      • Dec 07, 2015: True North Therapeutics Presents Data in Patients with Cold Agglutinin Disease Supporting Patient Profiles for TNT009 Phase 1b Study
      • Nov 13, 2015: Data shows that one dose of IdeS has favorable effect and completely removes HLA-antibodies
      • Nov 10, 2015: Data showing that IdeS can silence memory B-cells published in Journal of Immunology
      • Oct 30, 2015: Licensee's drug to commence Phase 2 and Phase 3 trials
      • Oct 13, 2015: Shire's CINRYZE (C1 esterase inhibitor [human]) Receives FDA Fast Track Designation for Investigation in the Treatment of Antibody Mediated Rejection in Patients Receiving Kidney Transplants
      • Sep 15, 2015: Data from Hansa Medical's First Phase II study of IdeS in Sensitized Kidney Transplantation Patients Presented in Oral Session at ESOT 2015
      • Sep 14, 2015: Hansa Medical receives FDA Orphan Drug Designation for IdeS
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for Kidney Transplantation, H1 2016
  • Number of Products under Development for Kidney Transplantation - Comparative Analysis, H1 2016
  • Number of Products under Development by Companies, H1 2016
  • Number of Products under Development by Companies, H1 2016 (Contd..1)
  • Number of Products under Investigation by Universities/Institutes, H1 2016
  • Comparative Analysis by Late Stage Development, H1 2016
  • Comparative Analysis by Clinical Stage Development, H1 2016
  • Comparative Analysis by Early Stage Development, H1 2016
  • Comparative Analysis by Unknown Stage Development, H1 2016
  • Products under Development by Companies, H1 2016
  • Products under Development by Companies, H1 2016 (Contd..1)
  • Products under Investigation by Universities/Institutes, H1 2016
  • Kidney Transplantation - Pipeline by Alexion Pharmaceuticals, Inc., H1 2016
  • Kidney Transplantation - Pipeline by Amgen Inc., H1 2016
  • Kidney Transplantation - Pipeline by Amyndas Pharmaceuticals LLC, H1 2016
  • Kidney Transplantation - Pipeline by Angion Biomedica Corp., H1 2016
  • Kidney Transplantation - Pipeline by Astellas Pharma Inc., H1 2016
  • Kidney Transplantation - Pipeline by Bio-inRen, H1 2016
  • Kidney Transplantation - Pipeline by Catalyst Biosciences, Inc., H1 2016
  • Kidney Transplantation - Pipeline by Corline Biomedical AB, H1 2016
  • Kidney Transplantation - Pipeline by CSL Limited, H1 2016
  • Kidney Transplantation - Pipeline by Digna Biotech, S.L., H1 2016
  • Kidney Transplantation - Pipeline by Dompe Farmaceutici S.p.A., H1 2016
  • Kidney Transplantation - Pipeline by Effimune SAS, H1 2016
  • Kidney Transplantation - Pipeline by FibroGen, Inc., H1 2016
  • Kidney Transplantation - Pipeline by GlaxoSmithKline Plc, H1 2016
  • Kidney Transplantation - Pipeline by Grifols, S.A., H1 2016
  • Kidney Transplantation - Pipeline by Hansa Medical AB, H1 2016
  • Kidney Transplantation - Pipeline by Kyowa Hakko Kirin Co., Ltd., H1 2016
  • Kidney Transplantation - Pipeline by Mabtech Limited, H1 2016
  • Kidney Transplantation - Pipeline by Noorik Biopharmaceuticals AG, H1 2016
  • Kidney Transplantation - Pipeline by Novartis AG, H1 2016
  • Kidney Transplantation - Pipeline by Opsona Therapeutics Limited, H1 2016
  • Kidney Transplantation - Pipeline by Pharming Group N.V., H1 2016
  • Kidney Transplantation - Pipeline by Prolong Pharmaceuticals, LLC, H1 2016
  • Kidney Transplantation - Pipeline by Quark Pharmaceuticals, Inc., H1 2016
  • Kidney Transplantation - Pipeline by Shire Plc, H1 2016
  • Kidney Transplantation - Pipeline by t-cell Europe GmbH, H1 2016
  • Kidney Transplantation - Pipeline by Tiziana Life Sciences Plc, H1 2016
  • Kidney Transplantation - Pipeline by Zyrnat Biotherapeutics SL, H1 2016
  • Assessment by Monotherapy Products, H1 2016
  • Number of Products by Stage and Target, H1 2016
  • Number of Products by Stage and Mechanism of Action, H1 2016
  • Number of Products by Stage and Route of Administration, H1 2016
  • Number of Products by Stage and Molecule Type, H1 2016
  • Kidney Transplantation Therapeutics - Recent Pipeline Updates, H1 2016
  • Kidney Transplantation - Dormant Projects, H1 2016
  • Kidney Transplantation - Dormant Projects (Contd..1), H1 2016
  • Kidney Transplantation - Dormant Projects (Contd..2), H1 2016
  • Kidney Transplantation - Discontinued Products, H1 2016

List of Figures

  • Number of Products under Development for Kidney Transplantation, H1 2016
  • Number of Products under Development for Kidney Transplantation - Comparative Analysis, H1 2016
  • Number of Products under Development by Companies, H1 2016
  • Comparative Analysis by Clinical Stage Development, H1 2016
  • Comparative Analysis by Early Stage Products, H1 2016
  • Assessment by Monotherapy Products, H1 2016
  • Number of Products by Top 10 Targets, H1 2016
  • Number of Products by Stage and Top 10 Targets, H1 2016
  • Number of Products by Top 10 Mechanism of Actions, H1 2016
  • Number of Products by Stage and Top 10 Mechanism of Actions, H1 2016
  • Number of Products by Routes of Administration, H1 2016
  • Number of Products by Stage and Routes of Administration, H1 2016
  • Number of Products by Top 10 Molecule Types, H1 2016
  • Number of Products by Stage and Top 10 Molecule Types, H1 2016
Back to Top